152 related articles for article (PubMed ID: 20926021)
41. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
42. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Shimatani T; Inoue M; Kuroiwa T; Horikawa Y
Aliment Pharmacol Ther; 2004 Jan; 19(1):113-22. PubMed ID: 14687173
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
44. Effect of a rabeprazole half-dose twice daily on acid inhibition in patients with different CYP2C19 alleles.
Murata M; Sugimoto M
Eur J Clin Pharmacol; 2020 Sep; 76(9):1253-1261. PubMed ID: 32488332
[TBL] [Abstract][Full Text] [Related]
45. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
Kodaira C; Uchida S; Yamade M; Nishino M; Ikuma M; Namiki N; Sugimoto M; Watanabe H; Hishida A; Furuta T
J Clin Pharmacol; 2012 Mar; 52(3):432-9. PubMed ID: 21415279
[TBL] [Abstract][Full Text] [Related]
46. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
[TBL] [Abstract][Full Text] [Related]
47. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
Williams MP; Sercombe J; Hamilton MI; Pounder RE
Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
[TBL] [Abstract][Full Text] [Related]
48. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
[TBL] [Abstract][Full Text] [Related]
49. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
50. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
51. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
52. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
[TBL] [Abstract][Full Text] [Related]
53. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
Yamano HO; Matsushita HO; Yanagiwara S
J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
[TBL] [Abstract][Full Text] [Related]
54. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
[TBL] [Abstract][Full Text] [Related]
56. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
Nishino M; Sugimoto M; Kodaira C; Yamade M; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
Dig Dis Sci; 2010 Jun; 55(6):1627-36. PubMed ID: 19672708
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
58. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
59. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Nakagawa K; Sugimura H; Ohashi K; Ishizaki T
Pharmacogenetics; 2001 Jun; 11(4):341-8. PubMed ID: 11434512
[TBL] [Abstract][Full Text] [Related]
60. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.
Sheng YC; Wang K; He YC; Yang J; Zheng QS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1165-9. PubMed ID: 20838991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
